{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:46:47Z","timestamp":1792414007103,"version":"4.4.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-54287-x","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T11:22:34Z","timestamp":1731756154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-863X","authenticated-orcid":false,"given":"Yi-Zong","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-5890","authenticated-orcid":false,"given":"Yi-Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keegan","family":"Braz Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Auclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn L.","family":"Stanfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linling","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6469-2419","authenticated-orcid":false,"given":"Ian A.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0259-7157","authenticated-orcid":false,"given":"Jiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,16]]},"reference":[{"key":"54287_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12016-013-8368-9","volume":"45","author":"AT Borchers","year":"2013","unstructured":"Borchers, A. T., Chang, C., Gershwin, M. E. & Gershwin, L. J. Respiratory syncytial virus - A comprehensive review. Clin. Rev. Allergy Immunol. 45, 331\u2013379 (2013).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"54287_CR2","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/CMR.00015-11","volume":"24","author":"V Schildgen","year":"2011","unstructured":"Schildgen, V. et al. Human metapneumovirus: lessons learned over the first decade. Clin. Microbiol. Rev. 24, 734\u2013754 (2011).","journal-title":"Clin. Microbiol. Rev."},{"key":"54287_CR3","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa043951","volume":"352","author":"AR Falsey","year":"2005","unstructured":"Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C. & Walsh, E. E. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352, 1749\u20131759 (2005).","journal-title":"N. Engl. J. Med."},{"key":"54287_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/INF.0b013e31822e68e6","volume":"31","author":"LJ Stockman","year":"2012","unstructured":"Stockman, L. J., Curns, A. T., Anderson, L. J. & Fischer-Langley, G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr. Infect. Dis. J. 31, 5\u20139 (2012).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"54287_CR5","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","volume":"390","author":"T Shi","year":"2017","unstructured":"Shi, T. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 390, 946\u2013958 (2017).","journal-title":"Lancet"},{"key":"54287_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12982-021-00104-5","volume":"18","author":"JAN Alonso","year":"2021","unstructured":"Alonso, J. A. N. et al. RSV: perspectives to strengthen the need for protection in all infants. Emerg. Themes Epidemiol. 18, 15 (2021).","journal-title":"Emerg. Themes Epidemiol."},{"key":"54287_CR7","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/89098","volume":"7","author":"BG van den Hoogen","year":"2001","unstructured":"van den Hoogen, B. G. et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat. Med. 7, 719\u2013724 (2001).","journal-title":"Nat. Med."},{"key":"54287_CR8","first-page":"122","volume":"5","author":"T Shi","year":"2015","unstructured":"Shi, T., McLean, K., Campbell, H. & Nair, H. Aetiological role of common respiratory viruses in acute lower respiratory infections in children under five years: A systematic review and meta-analysis. J. Glob. Health 5, 122\u2013131 (2015).","journal-title":"J. Glob. Health"},{"key":"54287_CR9","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1086\/513204","volume":"44","author":"G Boivin","year":"2007","unstructured":"Boivin, G. et al. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin. Infect. Dis. 44, 1152\u20131158 (2007).","journal-title":"Clin. Infect. Dis."},{"key":"54287_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1086\/367901","volume":"187","author":"AR Falsey","year":"2003","unstructured":"Falsey, A. R., Erdman, D., Anderson, L. J. & Walsh, E. E. Human metapneumovirus infections in young and elderly adults. J. Infect. Dis. 187, 785\u2013790 (2003).","journal-title":"J. Infect. Dis."},{"key":"54287_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/infdis\/jis333","volume":"206","author":"J Papenburg","year":"2012","unstructured":"Papenburg, J. et al. Comparison of risk factors for human metapneumovirus and respiratory syncytial virus disease severity in young children. J. Infect. Dis. 206, 178\u2013189 (2012).","journal-title":"J. Infect. Dis."},{"key":"54287_CR12","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1086\/344319","volume":"186","author":"G Boivin","year":"2002","unstructured":"Boivin, G. et al. Virological features and clinical manifestations associated with human metapneumovirus: A new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J. Infect. Dis. 186, 1330\u20131334 (2002).","journal-title":"J. Infect. Dis."},{"key":"54287_CR13","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3201\/eid0906.030017","volume":"9","author":"G Boivin","year":"2003","unstructured":"Boivin, G. et al. Human metapneumovirus infections in hospitalized children. Emerg. Infect. Dis. 9, 634\u2013640 (2003).","journal-title":"Emerg. Infect. Dis."},{"key":"54287_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1086\/421120","volume":"190","author":"AJ McAdam","year":"2004","unstructured":"McAdam, A. J. et al. Human metapneumovirus in children tested at a tertiary-care hospital. J. Infect. Dis. 190, 20\u201326 (2004).","journal-title":"J. Infect. Dis."},{"key":"54287_CR15","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3201\/eid1004.030555","volume":"10","author":"JA Mullins","year":"2004","unstructured":"Mullins, J. A. et al. Human metapneumovirus infection among children hospitalized with acute respiratory illness. Emerg. Infect. Dis. 10, 700\u2013705 (2004).","journal-title":"Emerg. Infect. Dis."},{"key":"54287_CR16","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1002\/cncr.30599","volume":"123","author":"F El Chaer","year":"2017","unstructured":"El Chaer, F. et al. Burden of human metapneumovirus infections in patients with cancer: risk factors and outcomes. Cancer 123, 2329\u20132337 (2017).","journal-title":"Cancer"},{"key":"54287_CR17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jcv.2014.08.019","volume":"61","author":"C Godet","year":"2014","unstructured":"Godet, C. et al. Human metapneumovirus pneumonia in patients with hematological malignancies. J. Clin. Virol. 61, 593\u2013596 (2014).","journal-title":"J. Clin. Virol."},{"key":"54287_CR18","doi-asserted-by":"publisher","first-page":"e2090","DOI":"10.1002\/rmv.2090","volume":"30","author":"MVM Divarathna","year":"2020","unstructured":"Divarathna, M. V. M., Rafeek, R. A. M. & Noordeen, F. A review on epidemiology and impact of human metapneumovirus infections in children using TIAB search strategy on PubMed and PubMed Central articles. Rev. Med. Virol. 30, e2090 (2020).","journal-title":"Rev. Med. Virol."},{"key":"54287_CR19","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.3201\/eid0912.030522","volume":"9","author":"LE Cuevas","year":"2003","unstructured":"Cuevas, L. E. et al. Human metapneumovirus and respiratory syncytial virus, Brazil. Emerg. Infect. Dis. 9, 1626\u20131628 (2003).","journal-title":"Emerg. Infect. Dis."},{"key":"54287_CR20","doi-asserted-by":"publisher","first-page":"010426","DOI":"10.7189\/jogh.10.010426","volume":"10","author":"Y Li","year":"2020","unstructured":"Li, Y., Pillai, P., Miyake, F. & Nair, H. The role of viral co-infections in the severity of acute respiratory infections among children infected with respiratory syncytial virus (RSV): A systematic review and meta-analysis. J. Glob. Health 10, 010426 (2020).","journal-title":"J. Glob. Health"},{"key":"54287_CR21","first-page":"3","volume":"372","author":"PL Collins","year":"2013","unstructured":"Collins, P. L., Fearns, R. & Graham, B. S. Respiratory syncytial virus: Virology, reverse genetics, and pathogenesis of disease. Curr. Top. Microbiol. Immunol. 372, 3\u201338 (2013).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"54287_CR22","first-page":"83","volume":"372","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S., Ray, W. C. & Peeples, M. E. Structure and function of respiratory syncytial virus surface glycoproteins. Curr. Top. Microbiol. Immunol. 372, 83\u2013104 (2013).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"54287_CR23","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1073\/pnas.1115941109","volume":"109","author":"M Magro","year":"2012","unstructured":"Magro, M. et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc. Natl Acad. Sci. Usa. 109, 3089\u20133094 (2012).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"54287_CR24","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/infdis\/jix489","volume":"216","author":"C Capella","year":"2017","unstructured":"Capella, C. et al. Prefusion F, postfusion F, G antibodies, and disease severity in infants and young children with acute respiratory syncytial virus infection. J. Infect. Dis. 216, 1398\u20131406 (2017).","journal-title":"J. Infect. Dis."},{"key":"54287_CR25","doi-asserted-by":"publisher","first-page":"309ra162","DOI":"10.1126\/scitranslmed.aac4241","volume":"7","author":"JO Ngwuta","year":"2015","unstructured":"Ngwuta, J. O. et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci. Transl. Med. 7, 309ra162 (2015).","journal-title":"Sci. Transl. Med."},{"key":"54287_CR26","doi-asserted-by":"publisher","first-page":"eaaj1879","DOI":"10.1126\/sciimmunol.aaj1879","volume":"1","author":"M Gilman","year":"2016","unstructured":"Gilman, M. et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci. Immunol. 1, eaaj1879 (2016).","journal-title":"Sci. Immunol."},{"key":"54287_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41579-019-0149-x","volume":"17","author":"MB Battles","year":"2019","unstructured":"Battles, M. B. & McLellan, J. S. Respiratory syncytial virus entry and how to block it. Nat. Rev. Microbiol. 17, 233\u2013245 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"54287_CR28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.vaccine.2016.09.045","volume":"35","author":"JA Melero","year":"2017","unstructured":"Melero, J. A., Mas, V. & McLellan, J. S. Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development. Vaccine 35, 461\u2013468 (2017).","journal-title":"Vaccine"},{"key":"54287_CR29","doi-asserted-by":"publisher","first-page":"e2203326119","DOI":"10.1073\/pnas.2203326119","volume":"119","author":"A Banerjee","year":"2022","unstructured":"Banerjee, A. et al. Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus. Proc. Natl Acad. Sci. Usa. 119, e2203326119 (2022).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"54287_CR30","doi-asserted-by":"publisher","first-page":"31642","DOI":"10.1074\/jbc.M102633200","volume":"276","author":"G Zimmer","year":"2001","unstructured":"Zimmer, G., Budz, L. & Herrler, G. Proteolytic activation of respiratory syncytial virus fusion protein - Cleavage at two furin consensus sequences. J. Biol. Chem. 276, 31642\u201331650 (2001).","journal-title":"J. Biol. Chem."},{"key":"54287_CR31","doi-asserted-by":"publisher","first-page":"9859","DOI":"10.1073\/pnas.151098198","volume":"98","author":"L Gonz\u00e1lez-Reyes","year":"2001","unstructured":"Gonz\u00e1lez-Reyes, L. et al. Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc. Natl Acad. Sci. USA 98, 9859\u20139864 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"54287_CR32","doi-asserted-by":"publisher","first-page":"e1005035","DOI":"10.1371\/journal.ppat.1005035","volume":"11","author":"MSA Gilman","year":"2015","unstructured":"Gilman, M. S. A. et al. Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLoS Pathog. 11, e1005035 (2015).","journal-title":"PLoS Pathog."},{"key":"54287_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9143","volume":"6","author":"A Krarup","year":"2015","unstructured":"Krarup, A. et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun. 6, 8143 (2015).","journal-title":"Nat. Commun."},{"key":"54287_CR34","doi-asserted-by":"publisher","first-page":"8942","DOI":"10.1128\/JVI.00676-08","volume":"82","author":"Y Shirogane","year":"2008","unstructured":"Shirogane, Y. et al. Efficient multiplication of human metapneumovirus in Vero cells expressing the transmembrane serine protease TMPRSS2. J. Virol. 82, 8942\u20138946 (2008).","journal-title":"J. Virol."},{"key":"54287_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01708-9","volume":"8","author":"MB Battles","year":"2017","unstructured":"Battles, M. B. et al. Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein. Nat. Commun. 8, 1528 (2017).","journal-title":"Nat. Commun."},{"key":"54287_CR36","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.immuni.2019.08.007","volume":"51","author":"TJ Ruckwardt","year":"2019","unstructured":"Ruckwardt, T. J., Morabito, K. M. & Graham, B. S. Immunological lessons from respiratory syncytial virus vaccine development. Immunity 51, 429\u2013442 (2019).","journal-title":"Immunity"},{"key":"54287_CR37","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.vaccine.2016.09.026","volume":"35","author":"A Mejias","year":"2017","unstructured":"Mejias, A., Garcia-Maurino, C., Rodriguez-Fernandez, R., Peeples, M. E. & Ramilo, O. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection. Vaccine 35, 496\u2013502 (2017).","journal-title":"Vaccine"},{"key":"54287_CR38","doi-asserted-by":"publisher","first-page":"e01714","DOI":"10.1128\/AAC.01714-16","volume":"61","author":"MP Griffin","year":"2017","unstructured":"Griffin, M. P. et al. Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob. Agents Chemother. 61, e01714\u2013e01716 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"54287_CR39","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/s41591-023-02316-5","volume":"29","author":"D Wilkins","year":"2023","unstructured":"Wilkins, D. et al. Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nat. Med. 29, 1172\u20131129 (2023).","journal-title":"Nat. Med."},{"key":"54287_CR40","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev-med-121217-094234","volume":"70","author":"BS Graham","year":"2019","unstructured":"Graham, B. S., Gilman, M. S. A. & McLellan, J. S. Structure-based vaccine antigen design. Annu. Rev. Med. 70, 91\u2013104 (2019).","journal-title":"Annu. Rev. Med."},{"key":"54287_CR41","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1056\/NEJMp2216358","volume":"388","author":"BS Graham","year":"2023","unstructured":"Graham, B. S. The journey to RSV vaccines - heralding an era of structure-based design. N. Engl. J. Med. 388, 579\u2013581 (2023).","journal-title":"N. Engl. J. Med."},{"key":"54287_CR42","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1126\/science.1234914","volume":"340","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113\u20131117 (2013).","journal-title":"Science"},{"key":"54287_CR43","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1243283","volume":"342","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592\u2013598 (2013).","journal-title":"Science"},{"key":"54287_CR44","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nsmb.3267","volume":"23","author":"MG Joyce","year":"2016","unstructured":"Joyce, M. G. et al. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat. Struct. Mol. Biol. 23, 811\u2013820 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"54287_CR45","doi-asserted-by":"publisher","first-page":"eade6422","DOI":"10.1126\/scitranslmed.ade6422","volume":"15","author":"Y Che","year":"2023","unstructured":"Che, Y. et al. Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine. Sci. Transl. Med. 15, eade6422 (2023).","journal-title":"Sci. Transl. Med."},{"key":"54287_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01858-w","volume":"8","author":"D Tian","year":"2017","unstructured":"Tian, D. et al. Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nat. Commun. 8, 1877 (2017).","journal-title":"Nat. Commun."},{"key":"54287_CR47","doi-asserted-by":"publisher","first-page":"16271","DOI":"10.1038\/nmicrobiol.2016.271","volume":"2","author":"JJ Mousa","year":"2017","unstructured":"Mousa, J. J., Kose, N., Matta, P., Gilchuk, P. & Crowe, J. E. Jr. A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein. Nat. Microbiol. 2, 16271 (2017).","journal-title":"Nat. Microbiol."},{"key":"54287_CR48","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.immuni.2018.01.005","volume":"48","author":"E Goodwin","year":"2018","unstructured":"Goodwin, E. et al. Infants infected with respiratory syncytial virus generate potent neutralizing antibodies that lack somatic hypermutation. Immunity 48, 339\u2013349.e5 (2018).","journal-title":"Immunity"},{"key":"54287_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12137-1","volume":"10","author":"AM Tang","year":"2019","unstructured":"Tang, A. M. et al. A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat. Commun. 10, 4153 (2019).","journal-title":"Nat. Commun."},{"key":"54287_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09807-5","volume":"10","author":"MSA Gilman","year":"2019","unstructured":"Gilman, M. S. A. et al. Transient opening of trimeric prefusion RSV F proteins. Nat. Commun. 10, 2105 (2019).","journal-title":"Nat. Commun."},{"key":"54287_CR51","doi-asserted-by":"publisher","first-page":"e1007944","DOI":"10.1371\/journal.ppat.1007944","volume":"15","author":"HG Jones","year":"2019","unstructured":"Jones, H. G. et al. Alternative conformations of a major antigenic site on RSV F. PLoS Pathog. 15, e1007944 (2019).","journal-title":"PLoS Pathog."},{"key":"54287_CR52","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.immuni.2021.03.004","volume":"54","author":"M Mukhamedova","year":"2021","unstructured":"Mukhamedova, M. et al. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. Immunity 54, 769\u2013780.e6 (2021).","journal-title":"Immunity"},{"key":"54287_CR53","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.coviro.2017.03.012","volume":"23","author":"BS Graham","year":"2017","unstructured":"Graham, B. S. Vaccine development for respiratory syncytial virus. Curr. Opin. Virol. 23, 107\u2013112 (2017).","journal-title":"Curr. Opin. Virol."},{"key":"54287_CR54","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","volume":"388","author":"A Papi","year":"2023","unstructured":"Papi, A. et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N. Engl. J. Med. 388, 595\u2013608 (2023).","journal-title":"N. Engl. J. Med."},{"key":"54287_CR55","doi-asserted-by":"publisher","first-page":"793","DOI":"10.15585\/mmwr.mm7229a4","volume":"72","author":"M Melgar","year":"2023","unstructured":"Melgar, M. et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices - United States, 2023. Morb. Mortal. Wkly. Rep. 72, 793\u2013801 (2023).","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"54287_CR56","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S1473-3099(22)00291-2","volume":"23","author":"N Mazur","year":"2023","unstructured":"Mazur, N. et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect. Dis. 23, e2\u2013e21 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"54287_CR57","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41579-023-00919-w","volume":"21","author":"AC Langedijk","year":"2023","unstructured":"Langedijk, A. C. & Bont, L. J. Respiratory syncytial virus infection and novel interventions. Nat. Rev. Microbiol. 21, 734\u2013749 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"54287_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00734-7","volume":"8","author":"TJ Ruckwardt","year":"2023","unstructured":"Ruckwardt, T. J. The road to approved vaccines for respiratory syncytial virus. npj Vaccines 8, 138 (2023).","journal-title":"npj Vaccines"},{"key":"54287_CR59","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/d41591-023-00017-7","volume":"29","author":"T Carvalho","year":"2023","unstructured":"Carvalho, T. mRNA vaccine effective against RSV respiratory disease. Nat. Med. 29, 755\u2013756 (2023).","journal-title":"Nat. Med."},{"key":"54287_CR60","doi-asserted-by":"publisher","first-page":"e1011584","DOI":"10.1371\/journal.ppat.1011584","volume":"19","author":"L Ou","year":"2023","unstructured":"Ou, L. et al. Structure-based design of a single-chain triple-disulfide-stabilized fusion-glycoprotein trimer that elicits high-titer neutralizing responses against human metapneumovirus. PLoS Pathog. 19, e1011584 (2023).","journal-title":"PLoS Pathog."},{"key":"54287_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28931-3","volume":"13","author":"CL Hsieh","year":"2022","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins. Nat. Commun. 13, 1299 (2022).","journal-title":"Nat. Commun."},{"key":"54287_CR62","doi-asserted-by":"publisher","first-page":"e2106196118","DOI":"10.1073\/pnas.2106196118","volume":"118","author":"GBE Stewart-Jones","year":"2021","unstructured":"Stewart-Jones, G. B. E. et al. Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses. Proc. Natl Acad. Sci. Usa. 118, e2106196118 (2021).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"54287_CR63","doi-asserted-by":"publisher","first-page":"16272","DOI":"10.1038\/nmicrobiol.2016.272","volume":"2","author":"X Wen","year":"2017","unstructured":"Wen, X. et al. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus. Nat. Microbiol. 2, 16272 (2017).","journal-title":"Nat. Microbiol."},{"key":"54287_CR64","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nature12442","volume":"501","author":"D Corti","year":"2013","unstructured":"Corti, D. et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501, 439\u2013443 (2013).","journal-title":"Nature"},{"key":"54287_CR65","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.immuni.2022.07.003","volume":"55","author":"CG Rappazzo","year":"2022","unstructured":"Rappazzo, C. G. et al. Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein. Immunity 55, 1710\u20131724.e8 (2022).","journal-title":"Immunity"},{"key":"54287_CR66","doi-asserted-by":"publisher","first-page":"e1008942","DOI":"10.1371\/journal.ppat.1008942","volume":"16","author":"J Huang","year":"2020","unstructured":"Huang, J., Diaz, D. & Mousa, J. J. Antibody recognition of the pneumovirus fusion protein trimer interface. PLoS Pathog. 16, e1008942 (2020).","journal-title":"PLoS Pathog."},{"key":"54287_CR67","doi-asserted-by":"publisher","first-page":"111399","DOI":"10.1016\/j.celrep.2022.111399","volume":"40","author":"SA Rush","year":"2022","unstructured":"Rush, S. A. et al. Characterization of prefusion-F-specific antibodies elicited by natural infection with human metapneumovirus. Cell Rep. 40, 111399 (2022).","journal-title":"Cell Rep."},{"key":"54287_CR68","doi-asserted-by":"publisher","first-page":"eabf1591","DOI":"10.1126\/sciadv.abf1591","volume":"7","author":"L He","year":"2021","unstructured":"He, L. et al. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. Sci. Adv. 7, eabf1591 (2021).","journal-title":"Sci. Adv."},{"key":"54287_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22867-w","volume":"12","author":"L He","year":"2021","unstructured":"He, L. et al. Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines. Nat. Commun. 12, 2633 (2021).","journal-title":"Nat. Commun."},{"key":"54287_CR70","doi-asserted-by":"publisher","first-page":"eaau6769","DOI":"10.1126\/sciadv.aau6769","volume":"4","author":"L He","year":"2018","unstructured":"He, L. et al. HIV-1 vaccine design through minimizing envelope metastability. Sci. Adv. 4, eaau6769 (2018).","journal-title":"Sci. Adv."},{"key":"54287_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12040","volume":"7","author":"L Kong","year":"2016","unstructured":"Kong, L. et al. Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. Nat. Commun. 7, 12040 (2016).","journal-title":"Nat. Commun."},{"key":"54287_CR72","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.1128\/JVI.76.9.4634-4642.2002","volume":"76","author":"XZ Yang","year":"2002","unstructured":"Yang, X. Z. et al. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 76, 4634\u20134642 (2002).","journal-title":"J. Virol."},{"key":"54287_CR73","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1128\/jvi.74.10.4746-4754.2000","volume":"74","author":"XZ Yang","year":"2000","unstructured":"Yang, X. Z. et al. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J. Virol. 74, 4746\u20134754 (2000).","journal-title":"J. Virol."},{"key":"54287_CR74","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.1128\/JVI.74.12.5716-5725.2000","volume":"74","author":"XZ Yang","year":"2000","unstructured":"Yang, X. Z., Farzan, M., Wyatt, R. & Sodroski, J. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 74, 5716\u20135725 (2000).","journal-title":"J. Virol."},{"key":"54287_CR75","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","volume":"176","author":"J Marcandalli","year":"2019","unstructured":"Marcandalli, J. et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell 176, 1420\u20131431.e17 (2019).","journal-title":"Cell"},{"key":"54287_CR76","doi-asserted-by":"publisher","first-page":"eaba6466","DOI":"10.1126\/sciimmunol.aba6466","volume":"5","author":"KA Swanson","year":"2020","unstructured":"Swanson, K. A. et al. A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain. Sci. Immunol. 5, eaba6466 (2020).","journal-title":"Sci. Immunol."},{"key":"54287_CR77","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nsmb.1723","volume":"17","author":"JS McLellan","year":"2010","unstructured":"McLellan, J. S. et al. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat. Struct. Mol. Biol. 17, 248\u2013250 (2010).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"54287_CR78","doi-asserted-by":"publisher","first-page":"12236","DOI":"10.1128\/JVI.01579-10","volume":"84","author":"JS McLellan","year":"2010","unstructured":"McLellan, J. S. et al. Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. J. Virol. 84, 12236\u201312244 (2010).","journal-title":"J. Virol."},{"key":"54287_CR79","doi-asserted-by":"publisher","first-page":"23545","DOI":"10.1021\/acsnano.3c06526","volume":"17","author":"K Braz Gomes","year":"2023","unstructured":"Braz Gomes, K. et al. Single-component multilayered self-assembling protein nanoparticles displaying extracellular domains of matrix protein 2 as a pan-influenza A vaccine. ACS Nano 17, 23545\u201323567 (2023).","journal-title":"ACS Nano"},{"key":"54287_CR80","doi-asserted-by":"publisher","first-page":"7788","DOI":"10.1128\/JVI.00555-11","volume":"85","author":"JS McLellan","year":"2011","unstructured":"McLellan, J. S., Yang, Y., Graham, B. S. & Kwong, P. D. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J. Virol. 85, 7788\u20137796 (2011).","journal-title":"J. Virol."},{"key":"54287_CR81","doi-asserted-by":"publisher","first-page":"e1003618","DOI":"10.1371\/journal.ppat.1003618","volume":"9","author":"RW Sanders","year":"2013","unstructured":"Sanders, R. W. et al. A next-generation cleaved, soluble HIV-1 env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).","journal-title":"PLoS Pathog."},{"key":"54287_CR82","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1016\/j.celrep.2020.03.025","volume":"30","author":"L Rutten","year":"2020","unstructured":"Rutten, L. et al. Structure-based design of prefusion-stabilized filovirus glycoprotein trimers. Cell Rep. 30, 4540\u20134550.e3 (2020).","journal-title":"Cell Rep."},{"key":"54287_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14158","volume":"8","author":"I Rossey","year":"2017","unstructured":"Rossey, I. et al. Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nat. Commun. 8, 14158 (2017).","journal-title":"Nat. Commun."},{"key":"54287_CR84","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1016\/j.vaccine.2023.04.021","volume":"41","author":"L Ma","year":"2023","unstructured":"Ma, L. et al. Structural interrogation of a trimeric prefusion RSV fusion protein vaccine candidate by a camelid nanobody. Vaccine 41, 3308\u20133316 (2023).","journal-title":"Vaccine"},{"key":"54287_CR85","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nsmb.2250","volume":"19","author":"X Wen","year":"2012","unstructured":"Wen, X. et al. Structure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic site. Nat. Struct. Mol. Biol. 19, 461\u2013463 (2012).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"54287_CR86","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1371\/journal.pone.0120098","volume":"10","author":"ME Bose","year":"2015","unstructured":"Bose, M. E. et al. Sequencing and analysis of globally obtained human respiratory syncytial virus A and B genomes. PLoS One 10, 22 (2015).","journal-title":"PLoS One"},{"key":"54287_CR87","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3389\/fimmu.2017.01025","volume":"8","author":"L He","year":"2017","unstructured":"He, L. et al. Hidden lineage complexity of glycan-dependent HIV-1 broadly neutralizing antibodies uncovered by digital panning and native-like gp140 trimer. Front. Immunol. 8, 1025 (2017).","journal-title":"Front. Immunol."},{"key":"54287_CR88","doi-asserted-by":"publisher","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","volume":"9","author":"Q Zhu","year":"2017","unstructured":"Zhu, Q. et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci. Transl. Med. 9, eaaj1928 (2017).","journal-title":"Sci. Transl. Med."},{"key":"54287_CR89","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jmb.2007.02.024","volume":"368","author":"H Wu","year":"2007","unstructured":"Wu, H. et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368, 652\u2013665 (2007).","journal-title":"J. Mol. Biol."},{"key":"54287_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24514-w","volume":"12","author":"Q Zhang","year":"2021","unstructured":"Zhang, Q. et al. Potent and protective IGHV3-53\/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. Nat. Commun. 12, 4210 (2021).","journal-title":"Nat. Commun."},{"key":"54287_CR91","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1126\/science.abg5268","volume":"372","author":"WN Voss","year":"2021","unstructured":"Voss, W. N. et al. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Science 372, 1108\u20131112 (2021).","journal-title":"Science"},{"key":"54287_CR92","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","volume":"184","author":"W Dejnirattisai","year":"2021","unstructured":"Dejnirattisai, W. et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 184, 2939\u20132954.e9 (2021).","journal-title":"Cell"},{"key":"54287_CR93","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jmb.2007.05.022","volume":"372","author":"E Krissinel","year":"2007","unstructured":"Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774\u2013797 (2007).","journal-title":"J. Mol. Biol."},{"key":"54287_CR94","doi-asserted-by":"publisher","first-page":"eabj3107","DOI":"10.1126\/sciadv.abj3107","volume":"7","author":"Y-N Zhang","year":"2021","unstructured":"Zhang, Y.-N. et al. Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. Sci. Adv. 7, eabj3107 (2021).","journal-title":"Sci. Adv."},{"key":"54287_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37742-z","volume":"14","author":"YN Zhang","year":"2023","unstructured":"Zhang, Y.-N. et al. Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimmers as HIV-1 vaccine candidates. Nat. Commun. 14, 1985 (2023).","journal-title":"Nat. Commun."},{"key":"54287_CR96","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1126\/science.aav9033","volume":"365","author":"MC Crank","year":"2019","unstructured":"Crank, M. C. et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science 365, 505\u2013509 (2019).","journal-title":"Science"},{"key":"54287_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46295-8","volume":"15","author":"SV Gidwani","year":"2024","unstructured":"Gidwani, S. V. et al. Engineered dityrosine-bonding of the RSV prefusion F protein imparts stability and potency advantages. Nat. Commun. 15, 2202 (2024).","journal-title":"Nat. Commun."},{"key":"54287_CR98","first-page":"e1820","volume":"6","author":"Y Sun","year":"2016","unstructured":"Sun, Y. & L\u00f3pez, C. B. Preparation of respiratory syncytial virus with high or low content of defective viral particles and their purification from viral stocks. Bio-protoc. 6, e1820 (2016).","journal-title":"Bio-protoc."},{"key":"54287_CR99","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jcv.2009.09.020","volume":"46","author":"AR Falsey","year":"2009","unstructured":"Falsey, A. R., Formica, M. A. & Walsh, E. E. Microneutralization assay for the measurement of neutralizing antibodies to human metapneumovirus. J. Clin. Virol. 46, 314\u2013317 (2009).","journal-title":"J. Clin. Virol."},{"key":"54287_CR100","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00281-018-0726-5","volume":"41","author":"S Fischinger","year":"2019","unstructured":"Fischinger, S., Boudreau, C. M., Butler, A. L., Streeck, H. & Alter, G. Sex differences in vaccine-induced humoral immunity. Semin. Immunopathol. 41, 239\u2013249 (2019).","journal-title":"Semin. Immunopathol."},{"key":"54287_CR101","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. Nat. Rev. Immunol. 16, 626\u2013638 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"54287_CR102","doi-asserted-by":"publisher","first-page":"941865","DOI":"10.3389\/fimmu.2022.941865","volume":"13","author":"JC Huang","year":"2022","unstructured":"Huang, J. C., Miller, R. J. J. & Mousa, J. J. J. A pan-pneumovirus vaccine based on immunodominant epitopes of the fusion protein. Front. Immunol. 13, 941865 (2022).","journal-title":"Front. Immunol."},{"key":"54287_CR103","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","volume":"388","author":"B Kampmann","year":"2023","unstructured":"Kampmann, B. et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N. Engl. J. Med. 388, 1451\u20131464 (2023).","journal-title":"N. Engl. J. Med."},{"key":"54287_CR104","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/infdis\/jix503","volume":"216","author":"J Falloon","year":"2017","unstructured":"Falloon, J. et al. An adjuvanted, postfusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults. J. Infect. Dis. 216, 1362\u20131370 (2017).","journal-title":"J. Infect. Dis."},{"key":"54287_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12041","volume":"7","author":"L He","year":"2016","unstructured":"He, L. et al. Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. Nat. Commun. 7, 12041 (2016).","journal-title":"Nat. Commun."},{"key":"54287_CR106","doi-asserted-by":"publisher","first-page":"eaaz6225","DOI":"10.1126\/sciadv.aaz6225","volume":"6","author":"L He","year":"2020","unstructured":"He, L. et al. Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines. Sci. Adv. 6, eaaz6225 (2020).","journal-title":"Sci. Adv."},{"key":"54287_CR107","doi-asserted-by":"crossref","unstructured":"Gasteiger E. et al. in The Proteomics Protocols Handbook, J. M. Walker, Ed. (Humana Press, Totowa, NJ, 2005), pp. 571-607.","DOI":"10.1385\/1-59259-890-0:571"},{"key":"54287_CR108","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1107\/S1744309110038212","volume":"66","author":"MA Elsliger","year":"2010","unstructured":"Elsliger, M. A. et al. The JCSG high-throughput structural biology pipeline. Acta Crystallogr. F: Struct. Biol. Commun. 66, 1137\u20131142 (2010).","journal-title":"Acta Crystallogr. F: Struct. Biol. Commun."},{"key":"54287_CR109","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","volume":"276","author":"Z Otwinowski","year":"1997","unstructured":"Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307\u2013326 (1997).","journal-title":"Methods Enzymol."},{"key":"54287_CR110","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D: Struct. Biol. 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. D: Struct. Biol."},{"key":"54287_CR111","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D: Struct. Biol. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D: Struct. Biol."},{"key":"54287_CR112","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/nsb1203-980","volume":"10","author":"H Berman","year":"2003","unstructured":"Berman, H., Henrick, K. & Nakamura, H. Announcing the worldwide Protein Data Bank. Nat. Struct. Biol. 10, 980 (2003).","journal-title":"Nat. Struct. Biol."},{"key":"54287_CR113","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nsmb.3115","volume":"22","author":"J Agirre","year":"2015","unstructured":"Agirre, J. et al. Privateer: software for the conformational validation of carbohydrate structures. Nat. Struct. Mol. Biol. 22, 833\u2013834 (2015).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"54287_CR114","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1107\/S2059798323003595","volume":"79","author":"J Agirre","year":"2023","unstructured":"Agirre, J. et al. The CCP4 suite: integrative software for macromolecular crystallography. Acta Crystallogr. D: Struct. Biol. 79, 449\u2013461 (2023).","journal-title":"Acta Crystallogr. D: Struct. Biol."},{"key":"54287_CR115","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jsb.2006.05.009","volume":"157","author":"G Tang","year":"2007","unstructured":"Tang, G. et al. EMAN2: An extensible image processing suite for electron microscopy. J. Struct. Biol. 157, 38\u201346 (2007).","journal-title":"J. Struct. Biol."},{"key":"54287_CR116","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"54287_CR117","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2013a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"54287_CR118","doi-asserted-by":"publisher","first-page":"e4792","DOI":"10.1002\/pro.4792","volume":"32","author":"EC Meng","year":"2023","unstructured":"Meng, E. C. et al. UCSF ChimeraX: tools for structure building and analysis. Protein Sci. 32, e4792 (2023).","journal-title":"Protein Sci."},{"key":"54287_CR119","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."},{"key":"54287_CR120","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/pro.3235","volume":"27","author":"TD Goddard","year":"2018","unstructured":"Goddard, T. D. et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 27, 14\u201325 (2018).","journal-title":"Protein Sci."},{"key":"54287_CR121","doi-asserted-by":"publisher","first-page":"pdb.prot065573","DOI":"10.1101\/pdb.prot065573","volume":"2011","author":"J Andris-Widhopf","year":"2011","unstructured":"Andris-Widhopf, J., Steinberger, P., Fuller, R., Rader, C. & Barbas, C. F. 3rd Generation of human scFv antibody libraries: PCR amplification and assembly of light- and heavy-chain coding sequences. Cold Spring Harb. Protoc. 2011, pdb.prot065573 (2011).","journal-title":"Cold Spring Harb. Protoc."},{"key":"54287_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17737-w","volume":"11","author":"GP Wen","year":"2020","unstructured":"Wen, G. P. et al. Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans. Nat. Commun. 11, 3971 (2020).","journal-title":"Nat. Commun."},{"key":"54287_CR123","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1016\/j.vaccine.2021.06.016","volume":"39","author":"R Raghunandan","year":"2021","unstructured":"Raghunandan, R., Higgins, D. & Hosken, N. RSV neutralization assays - use in immune response assessment. Vaccine 39, 4591\u20134597 (2021).","journal-title":"Vaccine"},{"key":"54287_CR124","doi-asserted-by":"publisher","first-page":"12608","DOI":"10.1128\/JVI.79.19.12608-12613.2005","volume":"79","author":"S Biacchesi","year":"2005","unstructured":"Biacchesi, S. et al. Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates. J. Virol. 79, 12608\u201312613 (2005).","journal-title":"J. Virol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54287-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54287-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54287-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T14:03:07Z","timestamp":1732111387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54287-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,16]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["54287"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-54287-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,16]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: J.Z. serves as the Co-Founder, Interim Chief Scientific Officer, Consultant, and Scientific Advisory Board member of Uvax Bio, LLC, and holds associated financial interests. Other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9939"}}